90 related articles for article (PubMed ID: 14968353)
1. Retention of lepirudin at the tip of a silicone catheter: a better catheter flush solution?
Horne MK; Inkellis E
Support Care Cancer; 2004 Apr; 12(4):278-81. PubMed ID: 14968353
[TBL] [Abstract][Full Text] [Related]
2. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices.
Horne MK; McCloskey DJ; Calis K; Wesley R; Childs R; Kasten-Sportes C
Pharmacotherapy; 2006 Sep; 26(9):1262-7. PubMed ID: 16945048
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin activity of lepirudin adsorbed to silicone (polydimethylsiloxane) tubing.
Horne MK; Brokaw KJ
Thromb Res; 2003; 112(1-2):111-5. PubMed ID: 15013282
[No Abstract] [Full Text] [Related]
4. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces.
Shanks RM; Sargent JL; Martinez RM; Graber ML; O'Toole GA
Nephrol Dial Transplant; 2006 Aug; 21(8):2247-55. PubMed ID: 16627606
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of relative perforating potential of central venous catheters: comparison of materials, selected models, number of lumens, and angles of incidence to simulated membrane.
Gravenstein N; Blackshear RH
J Clin Monit; 1991 Jan; 7(1):1-6. PubMed ID: 1999693
[TBL] [Abstract][Full Text] [Related]
6. [Removal of lepirudin used as an anticoagulant in mechanical autotransfusion with Cell-Saver 5].
Marx A; von Lüpke U; Tessmann R; Lindhoff-Last E
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Mar; 36(3):162-6. PubMed ID: 11324348
[TBL] [Abstract][Full Text] [Related]
7. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access.
Bleyer AJ; Mason L; Russell G; Raad II; Sherertz RJ
Infect Control Hosp Epidemiol; 2005 Jun; 26(6):520-4. PubMed ID: 16018426
[TBL] [Abstract][Full Text] [Related]
9. Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomized trial.
Schallom ME; Prentice D; Sona C; Micek ST; Skrupky LP
Crit Care Med; 2012 Jun; 40(6):1820-6. PubMed ID: 22488006
[TBL] [Abstract][Full Text] [Related]
10. Experimental approach to prevention of catheter-related central venous thrombosis.
Di Costanzo J; Sastre B; Choux R; Reynier JP; Noirclerc M; Cano N; Martin J
JPEN J Parenter Enteral Nutr; 1984; 8(3):293-7. PubMed ID: 6429367
[TBL] [Abstract][Full Text] [Related]
11. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis.
Dager WE; White RH
Ann Pharmacother; 2001; 35(7-8):885-90. PubMed ID: 11485140
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
13. Tip position of long-term central venous access devices used for parenteral nutrition.
DeChicco R; Seidner DL; Brun C; Steiger E; Stafford J; Lopez R
JPEN J Parenter Enteral Nutr; 2007; 31(5):382-7. PubMed ID: 17712146
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the postglomerular renal metabolism of lepirudin in healthy volunteers.
Kautzleben M; Stein G; Sperschneider H; Nowak G
Thromb Res; 2004; 113(3-4):187-95. PubMed ID: 15140582
[TBL] [Abstract][Full Text] [Related]
15. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
16. The effects of heparin flush on patency of the Groshong catheter: a pilot study.
Mayo DJ; Horne MK; Summers BL; Pearson DC; Helsabeck CB
Oncol Nurs Forum; 1996 Oct; 23(9):1401-5. PubMed ID: 8899756
[TBL] [Abstract][Full Text] [Related]
17. Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia.
Badger NO; Butler K; Hallman LC
Pharmacotherapy; 2004 Dec; 24(12):1800-3. PubMed ID: 15585446
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Lepor NE
Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
[TBL] [Abstract][Full Text] [Related]
19. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Central Venous Catheter Protein Adsorption and Water Infused Surface Protection Mechanisms.
Sutherland DW; Blanks ZD; Zhang X; Charest JL
Artif Organs; 2018 Nov; 42(11):E369-E379. PubMed ID: 30141204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
